Screener
Veradermics MANE Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income | 149 | 33 |
| Total other income, net | 2,630 | 515 |
| Loss before income taxes | (27,232) | (12,400) |
| Income tax benefit | — | — |
| Net loss | $(27,232) | $(12,400) |
| Net loss attributable to common stock | $(30,011) | $(14,582) |
| Net loss per share of common stock, basic and diluted | $(1.32) | $(19.79) |
| Weighted average common stock outstanding, basic and diluted | 22,704,124 | 736,933 |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's income tax?
- Veradermics (MANE) reported income tax of $0 in Q1 2026.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Veradermics's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude